Grace Halsey

Dr Turner reviews the profile of the individual who is most likely to benefit from lecanemab therapy.

The Alzheimer’s Association and the Society of Nuclear Medicine and Molecular Imaging (SNMMI) have released updated Appropriate Use Criteria (AUC) for amyloid and tau PET imaging, according to a statement from the Alzheimer’s Association. 1

The novel dual NMR agonist was scored significantly less "likable" when crushed and taken intranasally compared with oxycodone, the company reported.

Close monitoring for dnPPHTN during the first 2 weeks post-delivery is highly recommended for women determined to be at high risk for the hypertensive disorder of pregnancy.

An analysis of more than 8000 death certificates of persons with COPD has revealed that 65% were prescribed at least 1 fall-risk increasing drug (FRID) and that nearly one-third (30%) had a fall with injury 2 years before death. 1

Although the study missed the primary endpoint, subgroup analyses found variable efficacy based on baseline BECs, suggesting potential benefits in specific subgroups.

A single oral dose of Symbravo provided rapid migraine pain freedom and return to normal functioning within 2 hours, and sustained efficacy through 24 and 48 hours.

Todd Bertoch, MD, reviews the significant findings on relief of pain from the 2 pivotal studies and lauds the remarkable safety profile of the novel nonopoid analgesic Journavx.

Journavx is the first and only approved non-opioid oral pain signal inhibitor and the first new class of pain medicine approved in more than 20 years.

Mariano, a well-known researcher in regional anesthesiology and acute pain medicine, talks about the Journavx difference, including the drug's safety profile.